Organogenesis Reports Trial Results on PuraPly AM for Wound Healing in Diabetic Foot Ulcers

Why It Matters

The data validates a new adjunct therapy that could reduce healing time, amputations, and overall health‑care costs associated with diabetic foot ulcers.

Key Takeaways

• 170‑patient trial met primary endpoint at 12 weeks
• PuraPly AM showed higher closure rates than standard care alone
• Combines collagen matrix with polyhexamethylene biguanide antimicrobial
• Addresses bioburden, supporting faster diabetic foot ulcer healing
• Publication pending, could influence wound‑care market adoption

Pulse Analysis

Diabetic foot ulcers (DFUs) remain one of the most challenging complications of diabetes, affecting roughly 15 % of patients and accounting for billions of dollars in U.S. health‑care expenditures each year. Chronic non‑healing wounds increase the risk of infection, hospitalization, and lower‑extremity amputation, driving both clinical urgency and economic pressure. While standard of care—debridement, off‑loading, and moist dressings—offers modest success, the industry has been seeking adjunctive products that can accelerate granulation and control microbial load. In this environment, robust clinical evidence is essential to shift practice patterns.

Organogenesis’ PuraPly AM combines a native, cross‑linked collagen scaffold with polyhexamethylene biguanide (PHMB), an antimicrobial agent known for broad‑spectrum activity and low resistance risk. The 170‑patient, randomized controlled trial compared PuraPly AM plus standard of care against standard of care alone in patients with non‑healing DFUs. At the 12‑week primary endpoint, the combination arm achieved a statistically significant increase in complete wound closure, surpassing the control group by a clinically meaningful margin. The trial’s success validates the hypothesis that simultaneous matrix support and bioburden management can synergistically improve healing trajectories.

The forthcoming peer‑reviewed publication positions PuraPly AM as a compelling addition to the wound‑care armamentarium, potentially reshaping reimbursement models that currently favor cheaper dressings. Payers may view the demonstrated reduction in healing time as a cost‑offset, given the high expenses associated with prolonged DFU management and amputations. Moreover, the trial’s design sets a benchmark for future studies of bioactive dressings, encouraging manufacturers to incorporate antimicrobial‑collagen hybrids. If adoption accelerates, Organogenesis could capture a larger share of the growing $6 billion U.S. advanced wound‑care market.